Series: Cardiovascular outcome trials for diabetes drugs Saxagliptin and SAVOR-TIMI 53

Authors

  • Miles Fisher Department of Diabetes, Endocrinology & Clinical Pharmacology, Glasgow Royal Infirmary Glasgow, UK

DOI:

https://doi.org/10.15277/bjd.2019.213

Keywords:

diabetes, cardiovascular outcome trial, saxagliptin

Abstract

SAVOR-TIMI 53 was the first FDA-mandated cardiovascular outcome trial to be presented and published. It compared saxagliptin and placebo in 16,492 patients with type 2 diabetes. SAVOR-TIMI 53 demonstrated non-inferiority for major cardiovascular events (cardiovascular death, myocardial infarction, stroke) but not superiority. An unexpected statistically significant increase in adjudicated hospitalisation for heart failure was seen in the saxagliptin group. Post hoc analysis demonstrated that subjects at greatest risk for hospitalisation for heart failure had previous heart failure, an estimated glomerular filtration rate <60 mL/min, or elevated baseline levels of N-terminal pro-B type natriuretic peptide. As other dipeptidyl peptidase 4 (DPP-4) inhibitors are available which have not been associated with an increased risk of hospitalisation for heart failure, saxagliptin should be avoided in patients with heart failure or a reduced estimated glomerular filtration rate.

References

Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457–71. https://doi.org/10.1056/NEJMoa072761

Food and Drug Administration. Guidance for industry. Diabetes mellitus – evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2008. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf (accessed 9 Feb 2019).

European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. London: EMA, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf (accessed 9 Feb 2019).

Scirica BM, Bhatt DL, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26. https://doi.org/10.1056/NEJMoa1307684

White WB, Cannon CP, Heller SR, et al for the EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369;1327–35. https://doi.org/10.1056/NEJMoa1305889

Green JB, Bethel A, Armstrong PW, et al for the TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232–42. https://doi.org/10.1056/NEJMoa1501352

Rosenstock J, Perkovic V, Johansen OE, et al for the CARMELINA Investigators. Effects of linagliptin versus placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and high renal risk. The CARMELINA randomized clinical trial. JAMA 2019; 321:69–79. https://doi.org/10.1001/jama.2018.18269.

Pfeffer MA, Claggett B, Diaz R, et al for the ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247–57. https://doi.org/10.1056/NEJMoa1509225.

Marso SP, Daniels GH, Brown-Frandsen K, et al for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375:311–22. https://doi.org/10.1056/NEJMoa1603827

Marso SP, Bain SC, Consoli A, et al for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141

Holman RR, Bethel MA, Mentz RJ, et al for the EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228–39. https://doi.org/10.1056/NEJMoa1612917

Hernandez AF, Green JB, Janmohamed S, et al for the Harmony Outcomes Committees and Investigators. Albiglutide and cardiovascular outcomes in people with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised, placebo-controlled trial. Lancet 2018;392:1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X

Zinman B, Wanner C, Lachin JM, et al for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–28. https://doi.org/10.1056/NEJMoa1504720

Neal B, Perkovic V, Mahaffey KW, et al for the CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925

Wiviott SD, Bonaca MP, Mosenzon O, et al for the DECLARE-TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389

Marso SP, McGuire DK, Zinman B, et al for the DEVOTE Study Group. Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 2017;377:723–32. https://doi.org/10.1056/NEJMoa1615692

Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16–27. https://doi.org/10.3810/pgm.2010.05.2138

Scirica BM, Bhaat DL, Braunwald E, et al. The design and rationale of the Saxglitin Assessment of Vascualr Outcomes Recorded in patients with diabetes-mellitus-Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 study. Am Heart J 2011;162:818–25. https://doi.org/10.1016/j.ahj.2011.08.006

Mosenzon O, Raz I, Scirica BM, et al. Baseline characteristics of the patient population in the Saxaglitin Assessment of Vascualr Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial. Diabetes Metab Res Rev 2013;29:417–26. https://doi.org/10.1002/dmrr.2413

Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation 2014;130:1579–88. https://doi.org/10.1161/CIRCULATIONAHA.114.010389

Standl E, Erbach M, Schnell O. Dipeptidyl-peptidase-4 Inhibitors and heart failure: class effect, substance-specific effect, or chance effect? Curr Treat Options Cardiovasc Med 2014;16:353. https://doi.org/10.1007/s11936-014-0353-y

Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care 2017;40:69–76. https://doi.org/10.2337/dc16-0621

Haluzik M, Frolik J, Rychlik I. Renal effects of DPP-4 inhibitors: a focus on microalbuminuria. Int J Endocrinol 2013;2013:895102. https://doi.org/10.1155/2013/895102 [Epub 2013 Sep 5]

Udell JA, Bhatt DL, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:696–705. https://doi.org/10.2337/dc14-1850

Leiter LA, Teoh H, Braunwald E, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 2015;38:1145–53. https://doi.org/10.2337/dc14-2868

Cavender MA, Scirica BM, Raz I, et al. Cardiovascular outcomes of patients in SAVOR-TIMI 53 by baseline hemoglobin A1c. Am J Med 2016;129:340e1–8. https://doi.org/10.1016/j.amjmed.2015.09.022

Raz I, Bhatt DL, Hirshberg B, et al. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicentre trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. Diabetes Care 2014;37:2435–41. https://doi.org/10.2337/dc13-2546

Leiter LA, Teoh H, Mosenzon O, et al for the SAVOR-TIMI 53 Steering Committee and Investigators. Frequency of cancer events in the SAVOR-TIMI 53 trial. Diabetes Obes Metab 2015;18:186–90. https://doi.org/10.1111/dom.12582

Cahn A, Raz I, Mosenzon O, et al. Predisposing factors for any and major hypoglycaemia with saxagliptin versus placebo and overall: analysis from the SAVOR-TIMI 53 trial. Diabetes Care 2016;39:1329–37. https://doi.org/10.2337/dc15-2763

Downloads

Published

2019-06-27

Issue

Section

Current Topics